DUSA Pharmaceuticals (DUSA)
Your Dashboard
Displaying DUSA Charts
Personalize your Dashboard. You can add and remove charts, drag and drop them into the order you
like, and we'll save your settings for the next time you visit when you're logged in.
Log in here or Click here to register for your free account.
Select or add more charts
- Accounts Payable 1.332M
- Accounts Receivable 3.353M
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization 1.342
- Beneish M-Score Pro
- Beta Pro
- Book Value 28.16M
- Book Value per Share 1.142
- Capital Expenditures 0.1828M
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing -0.2271M
- Cash Financing TTM 0.1199M
- Cash Investing -0.1829M
- Cash Investing TTM 4.960M
- Cash Operations 1.223M
- Cash Operations TTM 7.682M
- Cash and Equivalents 25.24M
- Cash and ST Investments 29.02M
- Current Ratio 6.613
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio 0.00
- Dividend
- Dividend Yield 0.00%
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share -0.01
- Earnings Per Share Growth
- Earnings Per Share TTM 0.29
- Earnings Yield 5.33%
- Effective Tax Rate TTM Pro
- Enterprise Value 108.86M
- Expenses 13.76M
- Expenses TTM 40.15M
- Free Cash Flow 1.040M
- Free Cash Flow TTM 7.112M
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin 84.58%
- Gross Profit TTM 40.37M
- Income from Cont. Ops Pro
- Interest Expense 0.00
- Interest Income
- Inventories 3.223M
- KZ Index Pro
- Liabilities 10.76M
- Long Term Debt 0.00
- Market Cap 134.10M
- Net Income -0.3371M
- Net Income TTM 7.587M
- Net PP&E 1.837M
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio 18.76
- PE Value Pro
- PEG Ratio 0.1146
- PS Value Pro
- Payout Ratio TTM Pro
- Price 5.44
- Price / Book Value 4.762
- Price / Sales Ratio 2.809
- Price / Tangible Book Value Pro
- Profit Margin -2.51%
- R&D Expense 2.051M
- Receivables Turnover 16.83
- Retained Earnings -134.67M
- Retained Earnings Growth
- Return on Assets 22.24%
- Return on Equity 31.36%
- Return on Invested Capital Pro
- Revenue Growth 22.21%
- Revenue Per Share TTM 1.936
- Revenues 13.42M
- Revenues TTM 47.74M
- SG&A Expense 7.716M
- Shareholders Equity 28.16M
- Shares Outstanding 24.65M
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets 38.92M
- Total Return Price 5.44
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
What do these terms mean? Read all about them in the Glossary.
You may also be interested in these DUSA related companies
DUSA News
$DUSA - Initial Stop hit. Trade close @ Initial Stop of $5.10 - http://stks.co/3so5
about 12 days ago by TraderFoxxx
about 12 days ago by TraderFoxxx
$DUSA forms bearish "Diamond Top" chart pattern. http://stks.co/3mUY
about 18 days ago by RecogniaEvents
about 18 days ago by RecogniaEvents
Listen to $DUSA Q1 2012 earnings call - live at 08:30 AM, ondemand after - http://stks.co/3iR7
about 21 days ago by earningscast
about 21 days ago by earningscast
DUSA Pharmaceuticals Reports First Quarter 2012 Corporate Highlights and Financial Results
May 08, 6:30AM GlobeNewswire
May 08, 6:30AM GlobeNewswire
DUSA Pharmaceuticals Completes Enrollment in Phase 2 Studies of Levulan(R) Kerastick(R) Photodynamic Therapy
Apr 24, 7:30AM GlobeNewswire
Apr 24, 7:30AM GlobeNewswire
DUSA Pharmaceuticals Introduces Teeing Off Against Sun Damage(TM) Campaign to Raise Awareness of Actinic Keratosis
Apr 10, 8:30AM GlobeNewswire
Apr 10, 8:30AM GlobeNewswire
Trade Signal-New $DUSA -BTO @ 6.48-Limit w/5.10-Stop on the Wkly Chart w/.5N @ Risk http://chart.ly/t5llhwx
about 64 days ago by TraderFoxxx
about 64 days ago by TraderFoxxx
DUSA Pharmaceuticals to Present at the 2012 Maxim Group Growth Conference
Mar 23, 8:00AM GlobeNewswire
Mar 23, 8:00AM GlobeNewswire
$DUSA http://stks.co/2wc5 broke over lower range on volume of 150% of full day average - has a level overhead
about 71 days ago by StockTiger
about 71 days ago by StockTiger
DUSA Pharmaceuticals to Present at the 2012 Maxim Group Growth Conference
Mar 19, 8:30AM GlobeNewswire
Mar 19, 8:30AM GlobeNewswire
DUSA Pharmaceuticals to Present at Roth Capital Partners 24th Annual OC Growth Stock Conference
Mar 07, 8:30AM GlobeNewswire
Mar 07, 8:30AM GlobeNewswire
Listen to $DUSA Q4 2011 earnings call - live at 08:30 AM, ondemand after - http://stks.co/2giF
about 84 days ago by earningscast
about 84 days ago by earningscast
DUSA Pharmaceuticals Reports Full Year 2011 Corporate Highlights and Financial Results
Mar 06, 6:30AM GlobeNewswire
Mar 06, 6:30AM GlobeNewswire
DUSA Pharmaceuticals to Present at the Leerink Swann 2012 Global Healthcare Conference
Feb 08, 8:30AM GlobeNewswire
Feb 08, 8:30AM GlobeNewswire
DUSA Pharmaceuticals to Present at the 14th Annual BIO CEO & Investor Conference
Feb 06, 9:10AM GlobeNewswire
Feb 06, 9:10AM GlobeNewswire
DUSA Pharmaceuticals, Inc. (DUSA) CEO to Ring The NASDAQ Stock Market Opening Bell
Dec 21, 12:20PM GlobeNewswire
Dec 21, 12:20PM GlobeNewswire
DUSA Pharmaceuticals Reports Third Quarter 2011 Corporate Highlights and Financial Results
Nov 10, 6:30AM GlobeNewswire
Nov 10, 6:30AM GlobeNewswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| DUSA | 5.44 | +0.04 | +0.74% | 134.10M |
| DUK | 21.96 | +0.16 | +0.73% | 29.38B |
| DUG | 27.46 | +0.20 | +0.73% | |
| DUF | 14.83 | -0.07 | -0.47% | 515.79M |
| DUCK | 8.11 | +0.09 | +1.12% | 31.14M |
| DUC | 12.40 | +0.06 | +0.49% | |
| DTV | 46.40 | +0.03 | +0.06% | 31.39B |
| DRH | 9.85 | -0.01 | -0.10% | 1.661B |
| DRE | 13.72 | -0.07 | -0.51% | 3.569B |
| DRD | 6.24 | +0.06 | +0.97% | 240.18M |
